GO M400
Alternative Names: GO-M400Latest Information Update: 09 Jul 2026
At a glance
- Originator GO Therapeutics; Xyphos
- Developer GO Therapeutics
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 22 Apr 2026 Pharmacokinetics, pharmacodynamics, adverse events data from preclinical studies in Solid tumours presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
- 18 Dec 2024 Preclinical trials in Solid tumours in USA (Parenteral), prior to December 2024 (GO Therapeutics pipeline, December 2024)
- 02 Jan 2024 GO Therapeutics has patent protection for "CORE3-MUC1 binding polypeptides and uses thereof" in USA